Reviewing the potential use of scaffold-mediated localized chemotherapy in oncology

[1]Wadasadawala T, Vadgaonkar R, Bajpai J. Management of Isolated Locoregional Recurrences in Breast Cancer: A Review of Local and Systemic Modalities. Clin Breast Cancer. 2017 Nov; 17 (7): 493-502.WadasadawalaTVadgaonkarRBajpaiJManagement of Isolated Locoregional Recurrences in Breast Cancer: A Review of Local and Systemic ModalitiesClin Breast Cancer2017Nov17749350210.1016/j.clbc.2017.03.008Search in Google Scholar

[2]Harms W, Geretschläger A, Cescato C, Buess M, Köberle D, Asadpour B. Current Treatment of Isolated Locoregional Breast Cancer Recurrences. Breast Care 2015; 10: 265–271.HarmsWGeretschlägerACescatoCBuessMKöberleDAsadpourBCurrent Treatment of Isolated Locoregional Breast Cancer RecurrencesBreast Care20151026527110.1159/000439151Search in Google Scholar

[3]Elsayed M, Alhussini M, Basha A and Awad A. T. Analysis of loco-regional and distant recurrences in breast cancer after conservative surgery. World Journal of Surgical Oncology (2016) 14:144ElsayedMAlhussiniMBashaAandAwadA. T.Analysis of loco-regional and distant recurrences in breast cancer after conservative surgeryWorld Journal of Surgical Oncology20161414410.1186/s12957-016-0881-xSearch in Google Scholar

[4]Van Tienhoven G, Voogd AC, Peterse JL, et al.: Prognosis after treatment for locoregional recurrence after mastectomy or breast conserving therapy in two randomized trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group. Eur J Cancer 1999,35: 32–38.VanTienhoven GVoogdACPeterseJLet alPrognosis after treatment for locoregional recurrence after mastectomy or breast conserving therapy in two randomized trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative GroupEur J Cancer199935323810.1016/S0959-8049(98)00301-3Search in Google Scholar

[5]Karlsson P, Cole BF, Price KN, Gelber RD, Coates AS, Goldhirsch A. Timing of radiotherapy and chemotherapy after breast-conserving surgery for node-positive breast cancer: long-term results from IBCSG Trials VI and VIIInt J Radiat Oncol Biol Phys. 2016 October 1; 96(2): 273–279KarlssonPColeBFPriceKNGelberRDCoatesASGoldhirschATiming of radiotherapy and chemotherapy after breast-conserving surgery for node-positive breast cancer: long-term results from IBCSG Trials VI and VIIInt J Radiat Oncol Biol Phys2016October 196227327910.1016/j.ijrobp.2016.06.2448Search in Google Scholar

[6]Liu Y, Zhai X, Li J, Li Z, Ma D and Wang Z. Is there an optimal time to initiate adjuvant chemotherapy to predict benefit of survival in non-small cell lung cancer? Chin J Cancer Res. 2017; 29(3): 263–271LiuYZhaiXLiJLiZMaD and Wang ZIs there an optimal time to initiate adjuvant chemotherapy to predict benefit of survival in non-small cell lung cancer?Chin J Cancer Res201729326327110.21147/j.issn.1000-9604.2017.03.12Search in Google Scholar

[7]Chay C, Smith DC. Adjuvant and neoadjuvant therapy in prostate cancer. Semin Oncol. 2001; 28(1): 3-12.ChayCSmithDCAdjuvant and neoadjuvant therapy in prostate cancerSemin Oncol200128131210.1016/S0093-7754(01)90041-7Search in Google Scholar

[8]Dąbrowska A M, Słotwiński R. The immune response to surgery and infection. Centr Eur J Immunol 2014; 39 (4): 532-537DąbrowskaA MSłotwińskiRThe immune response to surgery and infectionCentr Eur J Immunol201439453253710.5114/ceji.2014.47741443996826155175Search in Google Scholar

[9]Gupta AA, Pande N, Kheur S, Raj AT. Assessing the potential role of scafold-mediated local chemotherapy in oral cancer. Oral Oncol. 2018. https://doi.org/10.1016/j.oraloncology.2018.03.009GuptaAAPandeNKheurSRajATAssessing the potential role of scafold-mediated local chemotherapy in oral cancerOral Oncol2018https://doi.org/10.1016/j.oraloncology.2018.03.00910.1016/j.oraloncology.2018.03.00929555306Search in Google Scholar

[10]Kretlow JD, Mikos AG. From material to tissue: biomaterial development, scafold fabrication, and tissue engineering. AIChE J. 2008; 54(12): 3048-67.KretlowJDMikosAGFrom material to tissue: biomaterial development, scafold fabrication, and tissue engineeringAIChE J2008541230486710.1002/aic.11610274350719756176Search in Google Scholar

[11]Langer R. Biomaterials in drug delivery and tissue engineering: one laboratory’s experience. Acc Chem Res. 2000; 33: 94–101.LangerRBiomaterials in drug delivery and tissue engineering: one laboratory’s experienceAcc Chem Res2000339410110.1021/ar9800993Search in Google Scholar

[12]Hutmacher DW. Scafolds in tissue engineering bone and cartilage. Biomaterials. 2000; 21: 2529–43.HutmacherDWScafolds in tissue engineering bone and cartilageBiomaterials20002125294310.1016/S0142-9612(00)00121-6Search in Google Scholar

[13]Shea LD, Smiley E, Bonadio J, Mooney DJ. DNA delivery frompolymer matrices for tissue engineering. Nat Biotechnol. 1999; 17: 551–4.SheaLDSmileyEBonadioJMooneyDJDNA delivery frompolymer matrices for tissue engineeringNat Biotechnol199917551410.1038/9853Search in Google Scholar

[14]Hoffman AS. Hydrogels for biomedical applications. Adv Drug Deliv Rev. 2002; 43: 3–12.HoffmanASHydrogels for biomedical applicationsAdv Drug Deliv Rev20024331210.1016/S0169-409X(01)00239-3Search in Google Scholar

[15]Drury JL, Mooney DJ. Hydrogels for tissue engineering: scaffold design variables and applications. Biomaterials. 2003; 24: 4337–51.DruryJLMooneyDJHydrogels for tissue engineering: scaffold design variables and applicationsBiomaterials20032443375110.1016/S0142-9612(03)00340-5Search in Google Scholar

[16]Lyons F, Partap S, O’Brien FJ. Part 1: scaffolds and surfaces. Technol Health Care. 2008; 16: 305–17.LyonsFPartapSO’BrienFJPart 1: scaffolds and surfacesTechnol Health Care2008163051710.3233/THC-2008-16409Search in Google Scholar

[17]Khang G, Lee SJ, Kim MS, Lee HB. Biomaterials: tissue engineering and scaffold. In Webster J (ed.). Encyclopedia of Medical Devices and Instrumentation, Vol 2; 2006: 366–83.KhangGLeeSJKimMSLeeHBBiomaterials: tissue engineering and scaffoldInWebsterJedEncyclopedia of Medical Devices and Instrumentation, Vol 22006366–8310.1002/0471732877.emd029Search in Google Scholar

[18]Chung HJ, Park TG. Surface engineered and drug releasing pre-fabricated scaffolds for tissue engineering. Adv Drug Deliv Rev. 2007;59:249–59.ChungHJParkTGSurface engineered and drug releasing pre-fabricated scaffolds for tissue engineeringAdv Drug Deliv Rev2007592495910.1016/j.addr.2007.03.01517482310Search in Google Scholar

[19]Karande ST, Agrawal MC. Functions and requirement of synthetic scaffolds in tissue engineering. In: Laurencin CT, Nair LS (eds.). Nanotechnology and Tissue Engineering: The Scaffolds; 2008:53.KarandeSTAgrawalMCFunctions and requirement of synthetic scaffolds in tissue engineeringInLaurencinCTNairLSedsNanotechnology and Tissue EngineeringThe Scaffolds20085310.1201/9781420051834.ch3Search in Google Scholar

[20]Ma PX. Biomimetic materials for tissue engineering. Adv Drug Deliv Rev. 2008; 60:184–98.MaPXBiomimetic materials for tissue engineeringAdv Drug Deliv Rev2008601849810.1016/j.addr.2007.08.041227103818045729Search in Google Scholar

[21]Drury JL, Mooney DJ. Hydrogels for tissue engineering: scaffold design variablesand applications. Biomaterials. 2003; 24: 4337–51.DruryJLMooneyDJHydrogels for tissue engineering: scaffold design variablesand applicationsBiomaterials20032443375110.1016/S0142-9612(03)00340-5Search in Google Scholar

[22]Hoffman AS. Hydrogels for biomedical applications. Adv Drug Deliv Rev. 2002; 43: 3–12.HoffmanASHydrogels for biomedical applicationsAdv Drug Deliv Rev20024331210.1016/S0169-409X(01)00239-3Search in Google Scholar

[23]Augst AD, Kong HJ, Mooney DJ. Alginate hydrogels as biomaterials. Macromol Biosci. 2006; 6: 623–33.AugstADKongHJMooneyDJAlginate hydrogels as biomaterialsMacromol Biosci200666233310.1002/mabi.20060006916881042Search in Google Scholar

[24]Huang S, Fu X. Naturally derived materials-based cell and drug delivery systems in skin regeneration. J Control Release. 2010;142:149–59.HuangSFuXNaturally derived materials-based cell and drug delivery systems in skin regenerationJ Control Release20101421495910.1016/j.jconrel.2009.10.01819850093Search in Google Scholar

[25]Park CJ, Clark SG, Lichtensteiger CA, Jamison RD, Johnson AJ. Accelerated wound closure of pressure ulcers in aged mice by chitosan scaffolds with and without bFGF. Acta Biomater. 2009; 5: 1926–36.ParkCJClarkSGLichtensteigerCAJamisonRDJohnsonAJAccelerated wound closure of pressure ulcers in aged mice by chitosan scaffolds with and without bFGFActa Biomater2009519263610.1016/j.actbio.2009.03.00219342320Search in Google Scholar

[26]Clark RAF, Singer AJ. Wound repair: basic biology to tissue engineering. London: Academic Press; 2000.ClarkRAFSingerAJWound repair: basic biology to tissue engineeringLondonAcademic Press200010.1016/B978-012436630-5/50065-9Search in Google Scholar

[27]Bradley M, Cullum N, Nelson EA, Petticrew M, Sheldon T, Torgerson D. Systematic reviews of wound care management: (2). Dressings and topical agents used in the healing of chronic wounds. Health Technol Assess. 1999; 3: 1–35.BradleyMCullumNNelsonEAPetticrewMSheldonTTorgersonDSystematic reviews of wound care management: (2)Dressings and topical agents used in the healing of chronic wounds. Health Technol Assess1999313510.3310/hta3172Search in Google Scholar

[28]Lee JE, Park JC, Lee HK, Oh SH, Suh H. Laminin modified infection-preventing collagen membrane containing silver sulfadiazine–hyaluronan microparticles. Artif Organs. 2002; 26: 521–8.LeeJEParkJCLeeHKOhSHSuhHLaminin modified infection-preventing collagen membrane containing silver sulfadiazine–hyaluronan microparticlesArtif Organs200226521810.1046/j.1525-1594.2002.06890.x12072108Search in Google Scholar

[29]Costa PF. Bone tissue engineering drug delivery. Current Molecular Biology Reports. 2015; 1: 87-93.CostaPFBone tissue engineering drug deliveryCurrent Molecular Biology Reports20151879310.1007/s40610-015-0016-0Search in Google Scholar

[30]Yao Q, Liu Y, Selvaratnam B, Ranjit T. Koodali D, Sun H. Mesoporous Silicate Nanoparticles/3D Nanofibrous Scaffold-mediated Dual-drug Delivery for Bone Tissue Engineering. doi:10.1016/j.jconrel.2018.04.011YaoQLiuYSelvaratnamBRanjitTKoodaliDSunHMesoporous Silicate Nanoparticles/3D Nanofibrous Scaffold-mediated Dual-drug Delivery for Bone Tissue Engineering10.1016/j.jconrel.2018.04.011597206629649529Open DOISearch in Google Scholar

[31]Agila S. Poornima J. Magnetically Controlled Nano-Composite Based 3D Printed Cell Scaffolds As Targeted Drug Delivery Systems For Cancer Therapy. Proceedings of the 15^th IEEE International Conference on Nanotechnology July 27-30, 2015, Rome, Italy.AgilaSPoornimaJMagnetically Controlled Nano-Composite Based 3D Printed Cell Scaffolds As Targeted Drug Delivery Systems For Cancer Therapy. Proceedings of the 15^th IEEE International Conference on Nanotechnology July 27-302015Rome, Italy10.1109/NANO.2015.7388803Search in Google Scholar

[32]Dai J, Jin J, Yang S and Li G. Doxorubicin-loaded PLA/pearl electrospun nanofibrous scaffold for drug delivery and tumor cells treatment. Mater. Res 2017. Express, at press: https://doi.org/10.1088/2053-1591/aa7479DaiJJinJYangS and Li GDoxorubicin-loaded PLA/pearl electrospun nanofibrous scaffold for drug delivery and tumor cells treatmentMater. Res2017Express, at presshttps://doi.org/10.1088/2053-1591/aa747910.1088/2053-1591/aa7479Search in Google Scholar

[33]Bagó J R., Pegna G J., Okolie O, Mohiti-Asli M, Loboa E G, Hingtgen S D. Electrospun nanofibrous scaffolds increase the efficacy of stem cell-mediated therapy of surgically resected glioblastoma DOI: 10.1016/j.biomaterials.2016.03.008BagóJ RPegnaG J.OkolieOMohiti-AsliMLoboaE GHingtgenS DElectrospun nanofibrous scaffolds increase the efficacy of stem cell-mediated therapy of surgically resected glioblastoma10.1016/j.biomaterials.2016.03.008Open DOISearch in Google Scholar

[34]Bao H, Zhang Q, Xu H, Yan Z. Effects of nanoparticle size on antitumor activity of 10-hydroxycamptothecin-conjugated gold nanoparticles: in vitro and in vivo studies. International Journal of Nanomedicine 2016:11 929–940.BaoHZhangQXuHYanZEffects of nanoparticle size on antitumor activity of 10-hydroxycamptothecin-conjugated gold nanoparticles: in vitro and in vivo studiesInternational Journal of Nanomedicine201611929–94010.2147/IJN.S96422Search in Google Scholar

[35]Chaudhari AA, Vig K, Baganizi DR, Sahu R, Dixit S, Dennis V et al. Future Prospects for Scaffolding Methods and Biomaterials in Skin Tissue Engineering: A Review. Int. J. Mol. Sci. 2016, 17, 1974; doi:10.3390/ijms17121974.ChaudhariAAVigKBaganiziDRSahuRDixitSDennisVet alFuture Prospects for Scaffolding Methods and Biomaterials in Skin Tissue Engineering: A ReviewInt. J. Mol. Sci201617197410.3390/ijms17121974Open DOISearch in Google Scholar

[36]Grigore ME. Drug Delivery Systems in Hard Tissue Engineering. SF J Biotechnol Biomed Eng. 2018; 1(1): 1001.GrigoreMEDrug Delivery Systems in Hard Tissue EngineeringSF J Biotechnol Biomed Eng2018111001Search in Google Scholar

[37]Garg T, Singh O, Arora S & Murthy RSR. Scaffold: A Novel Carrier for Cell and Drug Delivery. Critical Reviews™ in Therapeutic Drug Carrier Systems 2012; 29(1): 1–63.GargTSinghOAroraS&MurthyRSR.Scaffold: A Novel Carrier for Cell and Drug DeliveryCritical Reviews™ in Therapeutic Drug Carrier Systems201229116310.1615/CritRevTherDrugCarrierSyst.v29.i1.10Search in Google Scholar

[38]Jaisinghani A, Gupta A, Raj AT. The potential use of scaffold-mediated local delivery of bone modulators in accelerated orthodontics: A hypotheses. Medical Hypotheses 2018, doi: https://doi.org/10.1016/j mehy. 2018.07.005.JaisinghaniAGuptaARajATThe potential use of scaffold-mediated local delivery of bone modulators in accelerated orthodontics: A hypothesesMedical Hypotheses2018https://doi.org/10.1016/jmehy. 2018.07.00510.1016/j.mehy.2018.07.005Search in Google Scholar

[39]Aliperta, R, Welzel PB, Bergmann R, Freudenberg U, Berndt N, Feldmann A et al. Cryogel-supported stem cell factory for customized sustained release of bispecific antibodies for cancer immunotherapy. Sci. Rep. 7, 42855; doi: 10.1038/srep42855(2017).AlipertaRWelzelPBBergmannRFreudenbergUBerndtNFeldmannAet alCryogel-supported stem cell factory for customized sustained release of bispecific antibodies for cancer immunotherapySci. Rep74285510.1038/srep42855(2017)Open DOISearch in Google Scholar

[40]Lokteva A, Haberkorna U, Mier W. Multicyclic Peptides as Scaffolds for the Development of Tumor Targeting Agents. Current Medicinal Chemistry, 2016.LoktevaAHaberkornaUMierWMulticyclic Peptides as Scaffolds for the Development of Tumor Targeting AgentsCurrent Medicinal Chemistry201610.2174/092986732466617031612030428302013Search in Google Scholar